ArticleCancer discovery2021
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
168citing papers in PubMed, 1 pooled it
9.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- Intestinal microbiota and biliary system diseases.Frontiers in cellular and infection microbiology · 2024Pooled it
- Trial
- Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.Nature communications · 2025Trial
- Gut microbiota translocation and dissemination in health: can it be beneficial and purposeful?Gut microbes · 2026Review
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Advances in Exercise-Mediated Regulation of the Gut Microbiota via the Muscle-Gut Axis: Implications for Tumor Immunity and Treatment Responses.Metabolites · 2026Review
- Inflammatory gut-liver crosstalk: mechanisms and therapeutic targets.Experimental & molecular medicine · 2026Review
- Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Article
- The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention.Science China. Life sciences · 2026Review
- Article
- The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers · 2026Review
- Targeting mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Harnessing the microbiome for cancer therapy.Nature reviews. Microbiology · 2026Review
- CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer.Cancer immunology research · 2026Article
- Pre-diagnostic immunological markers of bacterial translocation and liver cancer risk: A nested case-control analysis of 12 prospective cohorts.International journal of cancer · 2026Article
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- Immunomodulatory Effects of Flavonoids in Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2026Review
- MSCs-derived CRABP2 regulates Treg/CXCL1 to ameliorate alcohol-induced liver injury.Cell communication and signaling : CCS · 2026Article
- Complement contributes to ICI-triggered sialadenitis and predicts ICI efficacy.Cancer immunology, immunotherapy : CII · 2026Article
- Gut microbiota drives cancer evolution and therapy resistance.Molecular cancer · 2026Review
108 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 8 institutions in 3 countries.
Qianfei ZhangGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Chi MaGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-4171-0813
Yi DuanDepartment of Medicine, University of California, San Diego, La Jolla, California.ORCID 0000-0002-6229-9461
Bernd HeinrichGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0003-0033-2462
Umberto RosatoGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Laurence P DiggsGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Lichun MaLaboratory of Human Carcinogenesis, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-4171-0813
Soumen RoyCancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Qiong FuGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Zachary J BrownGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-8347-9197
Simon WabitschGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-0915-4466
Vishal ThovaraiCancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Jianyang FuGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Dechun FengLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, Maryland.
Benjamin RufGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-2501-4471
Linda L CuiGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Varun SubramanyamGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Karen M FrankMicrobiology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland.
Sophie WangGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0001-9735-606X
David E KleinerLaboratory of Pathology, NIH, Bethesda, Maryland.
Thomas RitzInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Christian RuppDepartment of Gastroenterology, University Hospital of Heidelberg, Heidelberg, Germany.
Bin GaoLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, Maryland.
Thomas LongerichInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Alexander KroemerMedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, District of Columbia.ORCID 0000-0002-9842-4973
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.ORCID 0000-0001-9735-606X
Mathuros RuchirawatLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand.
Firouzeh KorangyGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Bernd SchnablDepartment of Medicine, University of California, San Diego, La Jolla, California.
Giorgio TrinchieriCancer and Inflammation Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Tim F GretenGastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. tim.greten@nih.gov.ORCID 0000-0002-0806-2535
Center for Cancer Research · USHeidelberg University · DENational Institute on Alcohol Abuse and Alcoholism · USUniversity of California San Diego · USChulabhorn Research Institute · THGeorgetown University · USNational Institutes of Health Clinical Center · USOffice of Extramural Research · US
Funding
Role of mouse microbiome in cancer and inflammationZIABC011153 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TRINCHIERI, GIORGIO · 2009 to 2025
$22.0MAnalysis of myeloid derived suppressor cells in miceZIABC011345 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$19.5MStrategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1MRole of inflammation, innate resistance, and immunity in carcinogenesis.ZIABC010793 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TRINCHIERI, GIORGIO · 2009 to 2025
$16.8MMolecular mechanisms of liver injury, repair, and immunityZIAAA000368 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GAO, BIN · 2009 to 2023
$16.1MThe role of cancer stem cells in liver cancer heterogeneity and subtypesZIABC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$12.6MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8MMicrobiome and Intestinal Innate Immune Response in Alcoholic Liver DiseaseR37AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2021 to 2026
$2.5MUPIT: Unleash the Potential of Intestinal TransplantationR01AI132389 · NIAID · GEORGETOWN UNIVERSITY · PI KROEMER, ALEXANDER HELMUT KURT · 2017 to 2021
$2.4MProtective and Proinflammatory Immunological Mechanisms behind Liver Ischemia Reperfusion Injury in Marginal LiversR21AI130800 · NIAID · GEORGETOWN UNIVERSITY · PI KROEMER, ALEXANDER HELMUT KURT · 2018 to 2019
$449kIntramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011345NIAAA NIH HHS R37 AA020703NIAID NIH HHS R01 AI132389NIAID NIH HHS R21 AI130800NIDDK NIH HHS P30 DK120515
Abstract
Gut dysbiosis is commonly observed in patients with cirrhosis and chronic gastrointestinal disorders; however, its effect on antitumor immunity in the liver is largely unknown. Here we studied how the gut microbiome affects antitumor immunity in cholangiocarcinoma. Primary sclerosing cholangitis (PSC) or colitis, two known risk factors for cholangiocarcinoma which promote tumor development in mice, caused an accumulation of CXCR2
Indexed as
AnimalsCholangiocarcinomaDisease Models, AnimalGastrointestinal MicrobiomeGram-Negative BacteriaHepatocytesHumansLiver NeoplasmsMiceMyeloid-Derived Suppressor Cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.